Short Summary
Syngenta Crop Protection AG's petition to invalidate Inflexion Point Technologies' patent was denied by the PTAB. The Board found insufficient evidence of anticipation or obviousness across multiple grounds, rejecting all challenges including enablement.
Detailed Summary
The Patent Trial and Appeal Board (PTAB) issued a denial decision in this case, finding that Petitioner Syngenta Crop Protection AG failed to establish a likelihood of unpatentability for any challenged claim of U.S. Patent No. 12102027. The challenges spanned anticipation (102), obviousness (103), and enablement (112). Key arguments centered on whether prior art disclosed the individual application of seed-applied substances, a limitation central to Claim 1. The Board ultimately found that the evidence did not meet the required threshold for institution, particularly regarding the scope of 'seed-applied substance' and the routine nature of the claimed method.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Syngenta Crop Protection AG vs Inflexion Point Technologies, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Arista Networks, Inc.vsOrckit Corporation
Arista Networks has filed an IPR petition challenging Orckit Corporation's patent (8,830,821) on grounds of obviousness (§103). The challenge centers on the combination of Doshi’s MPLS path selection with reoptimization techniques from prior art like Guichard and Huang.
WHOOP, Inc.vsOmni MedSci, Inc.
WHOOP petitions to invalidate claim 7 of Omni MedSci’s ’790 wearable sensor patent, asserting obviousness over multiple prior‑art references and indefiniteness under §112.
Samsung Electronics Co., Ltd et al.vsHEADWATER PARTNERS II LLC
Samsung has filed an IPR petition challenging all 34 claims of Headwater’s ’868 patent, arguing that the claims are obvious over the Jarvinen and Fox publications. The petition seeks institution of review and argues against discretionary denial.
Tempus AI, Inc.vsGuardant Health Inc.
The PTAB instituted an inter partes review of Guardant Health’s cfDNA sequencing patent after Foundation Medicine (Petitioner) showed a reasonable likelihood of success on an obviousness ground over several prior‑art references.
Micron Technology, Inc. et al.vsPalisade Technologies, LLP
Micron filed an unopposed motion to dismiss its IPR of U.S. Pat. No. 8,996,838 before the Board decided on institution, arguing that the proceeding was at an early stage and dismissal would conserve resources. The Board is expected to grant the motion, terminating the review.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.